Amadori S, Meloni G, Baccarani M, Haanen C, Willemze R, Corbelli G, Drenthe-Schonk A, Cardozo P L, Tura S, Mandelli F
Cancer. 1983 Jul 1;52(1):30-4. doi: 10.1002/1097-0142(19830701)52:1<30::aid-cncr2820520107>3.0.co;2-o.
Among 164 patients with acute lymphoblastic leukemia (ALL) (age greater than 11 years) induced into complete remission at four hospitals in Italy and The Netherlands between 1971-1977, 49 survived for more than three years in continuous complete remission. Features at diagnosis of the 49 long-term survivors were compared with those of the parent group. The long-term survivors presented with significantly lower leukocyte counts and were slightly younger. Late relapses occurred in nine patients after 37-91 months from remission. Of the 45 patients who had all treatment stopped after 24-60 months of continuous remission, seven have relapsed. Relapses, mainly in the marrow, occurred 4-32 months after cessation of therapy, the risk of relapse being greatest in the first year and dropping to zero by the fourth year. ALL appears curable in approximately one fifth of adolescents and adults entering complete remission with adequate chemotherapy.
1971年至1977年间，在意大利和荷兰的四家医院，164例急性淋巴细胞白血病（ALL）患者（年龄大于11岁）诱导进入完全缓解期，其中49例持续完全缓解超过三年。将49例长期存活者的诊断特征与母组进行比较。长期存活者的白细胞计数显著较低，年龄略小。9例患者在缓解后37至91个月出现晚期复发。在45例连续缓解24至60个月后停止所有治疗的患者中，7例复发。复发主要发生在骨髓，在治疗停止后4至32个月出现，复发风险在第一年最大，到第四年降至零。对于约五分之一通过充分化疗进入完全缓解期的青少年和成人，ALL似乎是可治愈的。
